We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01195454
First Posted: September 6, 2010
Last Update Posted: October 31, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Sanofi
  Purpose

Primary Objective:

- To assess the total metabolic effect ratios of a new insulin glargine formulation versus Lantus®

Secondary Objectives:

  • To assess the exposure ratios of a new insulin glargine formulation versus Lantus®
  • To compare the duration of action of a new insulin glargine formulation versus Lantus®
  • To explore the dose response and dose exposure relationship of a new insulin glargine formulation
  • To assess the safety and tolerability of a new insulin glargine formulation

Condition Intervention Phase
Type 1 Diabetes Mellitus Drug: Insulin glargine (HOE901) Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Sanofi:

Primary Outcome Measures:
  • The area under the body weight standardized glucose infusion rate curve (GIR) within 36 hours (GIR-AUC0-36) [ Time Frame: 36 hours (D1 to D2) in all four treatment periods ]

Secondary Outcome Measures:
  • The area under the insulin glargine concentration curve within 36 hours (INS-AUC0-36) - [ Time Frame: 36 hours (D1 to D2) in all four treatment periods ]
  • Time to 50% of the GIR-AUC0-36 (T50%-GIR AUC0-36) [ Time Frame: 36 hours (D1 to D2) in all four treatment periods ]
  • Time to 50% of INS-AUC0-36 (T50% INS-AUC0-36) [ Time Frame: 36 hours (D1 to D2) in all four treatment periods ]
  • Duration of blood glucose control (time to elevation of smoothed blood glucose profile above clamp level and to elevation above different pre-specified blood glucose levels) [ Time Frame: 36 hours (D1 to D2) in all four treatment periods ]
  • Maximum smoothed body weight standardized glucose infusion rate GIRmax, and time to GIRmax (GIR-Tmax) [ Time Frame: 36 hours (D1 to D2) in all four treatment periods ]
  • Maximum insulin concentration INS-Cmax, and time to Cmax (INS-Tmax) [ Time Frame: 36 hours (D1 to D2) in all four treatment periods ]

Enrollment: 24
Study Start Date: August 2010
Study Completion Date: December 2010
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Insulin glargine / New insulin glargine formulation
  • Period 1: Insulin glargine
  • Period 2: New insulin glargine formulation
  • Period 3: New insulin glargine formulation
  • Period 4: New insulin glargine formulation

Duration of treatment: 1 day at each period

Drug: Insulin glargine (HOE901)

Pharmaceutical form: Lantus solution for injection

Route of administration: subcutaneous

Drug: Insulin glargine (HOE901)

Pharmaceutical form: New insulin glargine formulation solution for injection

Route of administration: subcutaneous


Detailed Description:

The study period for one patient is one month in average and it can last up to 11 weeks broken down as follows:

  • Screening: 3 to 28 days
  • Treatment period: 1 to 4 days: 2 days (1 overnight stay)
  • Washout period: 5 to 18 days (preferentially 7 days between consecutive dosings)
  • End of study: 1 day after the last dosing
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Male or female subjects with diabetes mellitus type 1 for more than one year,
  • Total insulin dose of <1.2 U/kg/day,
  • Glycohemoglobin (HbA1c) ≤ 9.0%,
  • Fasting negative serum C-peptide (< 0.3 nmol/L),
  • Stable insulin regimen for at least 2 months prior to study,
  • Normal findings in medical history and physical examination (cardiovascular system, chest and lungs, thyroid, abdomen, nervous system, skin and mucosae, and musculo-skeletal system), vital signs, electrocardiogram (ECG) and safety lab,
  • Women of childbearing potential with negative pregnancy test and use of a highly effective contraceptive method or women with confirmed postmenopausal status.

Exclusion criteria:

  • Any history or presence of clinically relevant cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic (apart from diabetes mellitus type 1), hematological, neurological, psychiatric, systemic (affecting the body as a whole), ocular, gynecologic (if female), or infectious disease; any acute infectious disease or signs of acute illness,
  • More than one episode of severe hypoglycemia with seizure, coma or requiring assistance of another person during the past 6 months,
  • Frequent severe headaches and / or migraine, recurrent nausea and / or vomiting (more than twice a month),
  • Symptomatic hypotension (whatever the decrease in blood pressure), or asymptomatic postural hypotension defined by a decrease in SBP equal to or greater than 20 mmHg within three minutes when changing from the supine to the standing position,
  • Presence or history of a drug allergy or clinically significant allergic disease,
  • Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol,
  • Pregnant or breast feeding women,
  • Any medication (including St John's Wort) within 14 days before inclusion, or within 5 times the elimination half-life or pharmacodynamic half-life of that drug, whichever the longest and regular use of any medication other than insulins in the last month before study start with the exception of thyroid hormones, lipid-lowering and antihypertensive drugs, and, if female, with the exception of hormonal contraception or menopausal hormone replacement therapy; any vaccination within the last 28 days,
  • Positive reaction to any of the following tests: hepatitis B surface (HBs Ag) antigen, antihepatitis B core antibodies (anti-HBc Ab) if compound having possible immune activities, anti-hepatitis C virus (anti-HCV2) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab),
  • Known hypersensitivity to insulin glargine and excipients,
  • Any history or presence of deep leg vein thrombosis.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01195454


Locations
Germany
Sanofi-Aventis Administrative Office
Berlin, Germany
Sponsors and Collaborators
Sanofi
Investigators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT01195454     History of Changes
Other Study ID Numbers: PKD11627
2010-020914-27 ( EudraCT Number )
First Submitted: September 3, 2010
First Posted: September 6, 2010
Last Update Posted: October 31, 2011
Last Verified: October 2011

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin, Globin Zinc
Insulin
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs